Clinical trial · Observational
The Association Between TNFSF4 Polymorphism and CD
The Association Between Tumor Necrosis Factor Superfamily Member 4 Polymorphism and Crohn's Disease
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to investigate the associations between tumor necrosis factor superfamily member 4 (TNFSF4) gene polymorphisms and the risk of Crohn's disease (CD), and to elucidate the impact of TNFSF4 gene variations on the CD clinical phenotype and the efficacy of ustekinumab (UST). The main question it aims to answer is: Does TNFSF4 polymorphism affect susceptibility to CD and the efficacy of UST in CD patients? Participants will have their blood drawn upon enrollment
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis) | — | UNRESOLVED | — |
| Polymorphism, Single Nucleotide | — | UNRESOLVED | — |
| Ustekinumab | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ustekinumab - Standard Dosage | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- CD patients
- description
- Some CD patients received sufficient UST (6 mg/kg) intravenous infusion at week 0, followed by one subcutaneous (SC) dose of 90 mg UST at 8 weeks. Maintenance therapy consisted of 90 mg subcutaneous UST every 8 or 12 weeks.
- interventionNames
- Biological: Ustekinumab - Standard Dosage
- label
- normal controls
- description
- no biological agents treatment
Primary outcomes (1)
- measure
- the genotypes of TNFSF4
- timeFrame
- Baseline
- description
- multiplex polymerase chain reaction-ligase detection reaction technique
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * diagnosed CD based on comprehensive clinical, colonoscopy, histopathological, laboratory, and radiographic examination results Exclusion Criteria: * rheumatoid arthritis, systemic lupus erythematosus, intestinal tuberculosis, ischemic enteritis, radiation enteritis, tumors, etc.
References
Publications (0)
Data not yet available